Overview

Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to demonstrate the bioequivalence of 40 mg telmisartan / 5 mg amlodipine fixed dose combination vs. its monocomponents
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Amlodipine
Telmisartan
Telmisartan amlodipine combination